Armodafinil ARTVIGIL 150 mg-150 Artikel Modafinil / Modafinil Artvigil
|Time steps||up to 12 hours|
|Daily intake||300 mg|
|Compatible with alcohol||In small quantities|
Buy Armodafinil in US. Reviews Armodafinil 150
Treatment of sleepiness, improves memory and concentration.
Armodafinil belongs to the analeptics and ageratum (ageratum) — drugs that increase wakefulness without excessive stimulation of the CNS (in contrast to the amphetamines and their substituted derivatives).
Approved as a drug to increase wakefulness and decrease in sleepiness in patients with obstructive sleep apnea, narcolepsy, and people suffering from sleep disorder because of working in night time (with the so-called "syndrome night shift", code ICD-10 G47.26)
Armodafinil represents (R)-(−)-enantiomer of modafinil. Modafinil is a mixture of two enantiomers: (R)-(−)-modafinil and (S)-(+)-modafinil, sold under the name ARTVIGIL-150
Armodafinil enantiomer is the purest form of substances that promote wakefulness, or eugeroics. It consists of only (-) – (R) -enantiomer of racemic modafinil. Armodafinil was approved by the safety Administration of food and medicines USA (FDA) in June 2007.
Despite the fact that both substances have similar half-lives, armodafinil reaches its peak concentration in the blood later than modafinil, which can make it more effective as a substance that promotes wakefulness in patients with excessive daytime sleepiness.
Armodafinil currently approved by the FDA to treat excessive daytime sleepiness associated with obstructive sleep apnea, narcolepsy and shift work. It is widely used off-label for the treatment of the syndrome of attention deficit and hyperactivity disorder, chronic fatigue syndrome and major depressive disorder. It has been shown that it improves vigilance among air traffic controllers.
Armodafinil 150 mg approved by the US FDA for the treatment of narcolepsy and sleep disorders associated with shift work, as well as in the adjuvant treatment of obstructive sleep apnea. For the treatment of narcolepsy and obstructive sleep apnea, armodafinil is taken once a day at a dose of 150 mg or 250 mg in the morning. For the treatment of sleep disorders associated with shift work, Armodafinil take 150 mg dose one hour before starting work. Titration of the dose needed to mitigate some side effects.
In June 2010, it was revealed that the study armodafinil phase II adjunctive therapy in adults with schizophrenia failed to meet primary endpoints, and clinical program was subsequently ceased. However, a study published in the same year, showed that patients with schizophrenia treated with armodafinil, observed fewer negative symptoms of schizophrenia.
a Disorder of the circadian biorhythm in connection with the long flight
March 30, 2010 the FDA refused to approve the use of Armodafinil 150 for the treatment of disorders of biorhythms. 6)
In placebo-controlled studies, the most frequently observed side effects were headache, dry mouth, nausea, dizziness and insomnia. Possible side effects include depression, anxiety, hallucinations, euphoria, excessive activity and talkativeness, lack of appetite, tremor, thirst, rash, suicidal thoughts and aggression. The symptoms of overdose modafinilo include trouble sleeping, anxiety, confusion, disorientation, a feeling of excitement, delusions, hallucinations, nausea, diarrhea, extreme acceleration or deceleration of the heart rate, chest pain and high blood pressure.
armodafinil Mechanism of action is unknown. Armodafinil (R-modafinil) has pharmacological properties almost identical to modafinil (a mixture of R - and S-modafinil). Enantiomers R and S exhibit a similar pharmacological actions in animals. Armodafinil Artweger is a drug that promotes wakefulness, similar to sympathomimetic agents, including amphetamine and methylphenidate, although its pharmacologic profile is not identical to sympathomimetic amines. Armodafinil 150 is an indirect dopamine receptor agonist; it binds in vitro with the dopamine Transporter and inhibits the reuptake of dopamine. That of modafinil, this activity has been associated in vivo with increased extracellular dopamine levels. In mice, created using methods of genetic engineering and deprived of the dopamine Transporter (DAT), modafinil did not show activity related to the increased time of wakefulness, suggesting that this activity is DAT-dependent. However, the stimulating effects of modafinil, unlike amphetamine, did not oppose the effects of dopamine receptor antagonist haloperidol in rats. In addition, alpha-methyl-p-tyrosine, an inhibitor of dopamine synthesis, blocks the action of amphetamine, but does not block locomotor activity induced by modafinil.
In addition to the stimulating effects and ability to increase locomotor activity in animals, according to the leaflet of the drug Armodafinil , armodafinil produces psychoactive and euphoric effects, changing mood, perception, thinking and feelings typical of other stimulants of the Central nervous system (CNS) in humans. Armodafinil, racemic modafinil and may also have reinforcing properties, as evidenced by its self-use in monkeys that had previously learned to use cocaine. Artweger also partially considered a stimulant. Research by Cephalon in which patients were administered modafinil, methylphenidate, and placebo showed that modafinil produces "psychoactive and euphoric effects and feelings similar to those of methylphenidate."
Armodafinil has linear time-independent kinetics following single and repeated administration of oral dose. The increase in systemic exposure is proportional in the dose range of 50-400 mg. No time-dependent change in kinetics was observed through 12 weeks post-dose. Homeostasis for armodafinil developed within 7 days of taking the drug. At steady state, systemic exposure armodafinil 1.8 times higher than the exposure after a single dose. However, the average maximum concentration armodafinil at steady state was 37% higher after administration of 150 mg than the corresponding value after administration of modafinil 200 mg Provigil due to the more rapid removal of the S-enantiomer.
Armodafinil is readily absorbed after oral administration. The absolute oral bioavailability was not determined due to the aqueous insolubility armodafinil that ruled out intravenous. Peak concentration in plasma is approximately 2 h on an empty stomach. The effects of food on overall bioavailability armodafinil considered minimal; however, the time to reach peak concentrations may be delayed 2-4 hours when taken with food. Since the delay in time of maximum concentration is also associated with elevated plasma concentrations later in time, ingestion could potentially affect a beginning and a temporary course of pharmacological action armodafinil.